lncRNA PAX8-AS1 Serves as a Diagnostic Biomarker for Acute Coronary Syndrome and Predicts the Occurrence of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention.

Acute coronary syndrome (ACS) is a critical, life-threatening condition and a major cause of cardiovascular mortality and morbidity worldwide. The aim of this study was to investigate the clinical value of PAX8 antisense RNA 1 (PAX8-AS1) in ACS patients and to explore the effects of PAX8-AS1 on proliferation, apoptosis and migration of human umbilical vein endothelial cells (HUVECs). A total of 117 patients with ACS, including 62 patients with unstable angina pectoris (UAP) and 55 patients with acute myocardial infarction (AMI) were enrolled. RT-qPCR was used to detect the level of PAX8-AS1, and the diagnostic and prognostic value of PAX8-AS1 was analyzed using receiver operating characteristic (ROC) analysis and Kaplan-Meier analysis. Cell proliferation was detected with Cell Counting Kit-8 (CCK-8), cell apoptosis rate was detected by flow cytometry, and cell migration ability was detected by transwell assay. The binding relationship between PAX8-AS1 and miR-15a-5p was verified by dual-luciferase reporter gene assay. PAX8-AS1 was upregulated in the serum of ACS patients and had diagnostic value for ACS. PAX8-AS1 could distinguish UAP and AMI patients. High levels of PAX8-AS1 predicted the occurrence of major adverse cardiovascular events (MACEs) after percutaneous coronary intervention (PCI). In addition, PAX8-AS1 affected the proliferation, apoptosis and migration of HUVECs, and regulated the expression of miR-15a-5p. Therefore, PAX8-AS1 may be a biomarker for ACS.